Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic H... (n pursues a growth strategy combining in...)

Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia

Date:2/12/2008

n pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

Watson is committed to providing innovative solutions in urology care. With seven products currently available to address conditions ranging from overactive bladder to prostate cancer, Watson continues to support research that not only treats the symptoms associated with urological conditions, but that helps make urology patients' lives more livable. The Watson portfolio in the U.S. includes Oxytrol(R); Trelstar(R) LA; Trelstar(R) Depot; Androderm(R); AndroGel(R), under a co-promotion agreement with Solvay Pharmaceuticals, Inc.; and ProQuin(R) XR, under a co-promotion agreement with Depomed, Inc. In addition to silodosin, the Watson urology portfolio includes a number of products under development; Uracyst(R), for the treatment of interstitial cystitis; a six-month formulation of Trelstar(R) (triptorelin pamoate for injectable suspension), for the treatment of advanced prostate cancer; and oxybutynin topical gel, for overactive bladder.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

About Kissei Pharmaceutical Co., Ltd.

Kissei Pharmaceutical Co., Ltd., headquartered in Matsumoto, Nagano prefecture, founded in 1946, is a Japanese pharmaceutical company that develops, manufactures, markets, sells and distributes brand pharmaceutical products. Kissei is primarily focused on three important fields of new drug research: urogenital, endocrinology & metabolism and immunology & allergy.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Exc
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
2. Watson Launches Generic Biaxin(R) XL
3. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
4. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
5. Emisphere Technologies Announces Positive Results From Animal Studies on Oral B12 Using eligen(R) Technology
6. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
7. IDM Pharma Announces Phase 3 Mifamurtide (L-MTP-PE) Study Demonstrating Improved Survival Published in the Journal of Clinical Oncology
8. TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
9. Inverseon Announces Positive Phase IIa Asthma Study
10. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
11. N30 Pharma Announces Successful Initiation of Human Studies With N30-201

Post Your Comments:

(Date:12/15/2009)... CLEVELAND, Dec. 15 At today,s regular meeting ... (NYSE: LZ ), the board declared a ... March 10, 2010 to holders of record at the ... About The Lubrizol Corporation ,, The Lubrizol Corporation ... chemical company that produces and supplies technologies that improve ...

(Date:12/15/2009)... Today, Hill-Rom Holdings, Inc. (NYSE: HRC ... strategic and financial initiatives at its Investor Conference ... hosted by Peter H. Soderberg, president and CEO ... following topics: ,, Status of multi-year strategic ... financial updates Smart technologies that interface with ...

(Date:12/15/2009)... Rib-X Pharmaceuticals, Inc., a company focused ... drugs for the treatment of serious multi-drug-resistant infections ... research agreement with Massachusetts General Hospital (MGH). ... collaboration, Dr. David Hooper of MGH will evaluate ... model to determine resistance development and to validate ...

Breaking Medicine Technology:Lubrizol Declares Dividend 2 Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 2 Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 3 Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 4 Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 5 Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 6 Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies 7 Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 2 Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital 3 Smart Post Brings Scrubs 26amp 3B Beyond to Canadian Doorsteps 60656 1 Smart Post Brings Scrubs 26amp 3B Beyond to Canadian Doorsteps 60656 2 Gastroenterology hepatology societies release report evaluating fellowship training curriculum 60651 1 Gastroenterology hepatology societies release report evaluating fellowship training curriculum 60651 2 Gastroenterology hepatology societies release report evaluating fellowship training curriculum 60651 3 Tags reveal white sharks have neighborhoods in the north Pacific say Stanford researchers 10622 1 Tags reveal white sharks have neighborhoods in the north Pacific say Stanford researchers 10622 2 Tags reveal white sharks have neighborhoods in the north Pacific say Stanford researchers 10622 3 Tags reveal white sharks have neighborhoods in the north Pacific say Stanford researchers 10622 4

[0] Lubrizol Declares Dividend [0] Hill-Rom Investor Conference Features Business Strategy Updates and New Technologies [0] Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital

... for XIENCE V with No,Late Stent Thrombosis ... Three Years, BARCELONA, Spain, May 22, 2007 ... trial demonstrated no,additional Major Adverse Cardiac Events ... treated with either Abbott's XIENCE(TM) V,Everolimus Eluting ...

... of SEROQUEL XR--, WILMINGTON, Del., May 22, ... analyses from a large-scale,study that investigated the ... a once-daily medicine for the,treatment of schizophrenia ... annual meeting of the American Psychiatric Association,(APA). ...

Other Medicine Technology:Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 2 Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 3 Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials 4 New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 2 New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 3 New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 4 New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 5 New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 6 New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 7 New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 8 New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 9

Abbott Announces Continued Positive Results with Xience V,Everolimus Eluting Coronary Stent in Spirit Clinical Trials New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia

(Date:12/15/2009)... Study examines potential for injury when doctors decide benefits ... (HealthDay News) -- MRI scans can pose a serious ... U.S. Food and Drug Administration researchers exposed pacemakers to ... electrical voltage produced at the tip of the pacemaker ... patient,s heart. , The exposure to MRI magnetic pulses ...

(Date:12/15/2009)... Dec. 15 Accelify is proud to announce ... of Advisors. David will serve as Director of Development ... Accelify,s National Board of Advisors. ,, David ... District,s Board of Education in June 1995. As the ... of over 600,000 stretching from Northeast Los Angeles through ...

(Date:12/15/2009)... Mergers and acquisitions are commonplace today. ... globally or complete a product portfolio they also ... safety programs. ,, A new free, white paper ... a Hearing Conservation Program: US Airways ," details ... West led the newly formed company to enhance ...

(Date:12/15/2009)... -- Reportlinker.com announces that a new ... its catalogue: ,, The ... Market Forecasts to 2015, Competitive Benchmarking, ... ,, http://www.reportlinker.com/p0168100/The-Future-of-Autoimmune-Diseases-Therapeutics---Market-Forecasts-to-2015-Competitive-Benchmarking-Product-Pipeline-and-Deals-Analysis.html ,, ... has released its latest research "The ...

(Date:12/15/2009)... CHICAGO, Dec. 15 Research shows a ... return on investment as building a culture of ... improved performance(1). According to a new white paper ... wellness solutions, the workplace represents an ideal setting ... and building and sustaining a corporate culture of ...

[0] Patients With Pacemakers Should Avoid MRI Scans [0] Accelify Announces the Addition of David Tokofsky to its National Board of Advisors [0] New White Paper Details Best Practices of an Occupational Hearing Conservation Program: US Airways [0] Reportlinker Adds The Future of Autoimmune Diseases Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis [0] Optimizing Corporate Culture is Critical to the Success of Wellness Programs

... is an early or predisposing event in the pathogenesis ... research which appears online on September 23 in the ... Myelodysplastic syndrome is a heterogeneous group of diseases ... hematopoietic lineages, clonal evolution and a tendency to progress ...

... been used widely in the treatment of hypertension ... hypertension guidelines. Moreover, after myocardial infarction and in ... blockers prevents re-infarction, hospitalisation for heart failure, and ... that atenolol is not very effective in hypertension. ...

... of bleeding from solid abdominal organs has been traditionally ... which has latelybeen recognized as detrimental. // Although there ... hemorrhage, bleeding is still the direct cause of death ... ,There is a continuous search for the "magical drug" ...

... has produced two Anti-retrovirals which can be used ... Nevirapine and Zidovudine is produced by CMSI in ... two drugs were officially released by Sebastian Ouseperamppil, ... which could maintain the quality control and Research ...

... Reddy Union Minister of Information, Broadcasting and Culture, India ... public regarding the prevention and treatment of HIV infections. ... social relevance. The media could play an important role ... the different broadcasting tools such as radio, websites, SMS, ...

... study, published in the October issue of the journal ... immune system abnormalities, including reduced levels of NKT cells, ... cells in the liver regulate production of cytokines, which ... may contribute to obesity -related liver disease. ,The ...

Other Medicine News:Health News:Evidence against use of Beta blockers as first choice in the treatment of primary hypertension 2 Health News:Aprotinin in the treatment of hemorrhagic shock trauma patients 2 Health News:Obesity As A Contributor To Liver Disease 2

Chronic Exposure To Benzene May Result In Dysplasia Evidence against use of Beta blockers as first choice in the treatment of primary hypertension Aprotinin in the treatment of hemorrhagic shock trauma patients CMSI produces Low cost Anti-retroviral drugs in India Indian Minister wanted Media to Propaganda HIV/AIDS awareness Obesity As A Contributor To Liver Disease

Joseph Double Hook 10 mm wide. Designated most popular model or size....

Exceptional comfort, handling and eye health with a convenient replacement schedule. Suitable for wearers seeking the ideal combination of convenience and performance in a planned replacement soft le...

The proven daily wear spherical soft contact lens....

Acuvue2 is designed to be worn as a two-week daily wear lens (which means you take the lenses out each night). It can also be worn as a one-week extended wear lens (which means you can sleep in them)...

Medicine Products:

Joseph Double Hook Frequency 55 Sphere Cibasoft Acuvue2

Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic H...(n pursues a growth strategy combining in...),Health